Gland Pharma (NSE:GLAND) Total Equity: ₹103,580 Mil (As of Mar. 2026)


NSE:GLAND Gland Pharma Ltd NSE:GLAND
83 GF Score
Price ₹2,314.80
GF Value ₹2,125.65
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Gland Pharma Total Equity?

Gland Pharma NSE:GLAND -0.49% 83 Total Equity is ₹103,580 Mil as of Mar. 2026. GuruFocus rates NSE:GLAND with a GF Score™ of 83/100 and a GF Value™ of ₹2,125.65 (Fairly Valued). The stock has 6 warning signs investors should review.

Gland Pharma's total equity for the quarter that ended in Mar. 2026 was ₹103,580 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Gland Pharma Total Equity Historical Data

* Premium members only.

The historical data trend for Gland Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gland Pharma Total Equity Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only 71,576.21 79,587.22 87,238.43 91,507.41 103,579.50

Gland Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 91,507.41 0.00 95,626.03 0.00 103,579.50
NSE:GLAND
83GF Score
Gland Pharma Ltd NSE:GLAND
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Gland Pharma's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=125108.48-21528.98
=103,580

Gland Pharma's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=125108.48-21528.98
=103,580

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹103,580 Mil mean?
Gland Pharma (NSE:GLAND) has a Total Equity of ₹103,580 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Gland Pharma and its competitors.
Is Gland Pharma's Total Equity too high?
Gland Pharma's current Total Equity is ₹103,580 Mil. Overall, Gland Pharma has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Total Equity compare to ZTS and UTHR?
Gland Pharma's Total Equity of ₹103,580 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Gland Pharma and its competitors. Gland Pharma's current Total Equity is ₹103,580 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,125.65, compared to a current price of ₹2,314.80 — trading 8.9% above its estimated fair value. The current Total Equity is ₹103,580 Mil. Gland Pharma's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Total Equity is ₹103,580 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,314.80 is trading 8.9% above its estimated GF Value™ of ₹2,125.65. GuruFocus considers Gland Pharma to be Fairly Valued.

Key valuation signals for NSE:GLAND:

  • Total Equity: ₹103,580 Mil
  • GF Value™: ₹2,125.65 vs. price of ₹2,314.80 (8.9% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
83GF Score

Get the complete analysis for NSE:GLAND

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,314.80
Price
₹2,125.65
GF Value